MA29785B1 - Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr - Google Patents

Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr

Info

Publication number
MA29785B1
MA29785B1 MA30754A MA30754A MA29785B1 MA 29785 B1 MA29785 B1 MA 29785B1 MA 30754 A MA30754 A MA 30754A MA 30754 A MA30754 A MA 30754A MA 29785 B1 MA29785 B1 MA 29785B1
Authority
MA
Morocco
Prior art keywords
agents
preventing
treating disorders
disorders involving
receptor modulation
Prior art date
Application number
MA30754A
Other languages
English (en)
Inventor
Andrew Robert Marks
Donald W Landry
Shixian Deng
Zhen Zhuang Cheng
Stephan E Lehnart
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of MA29785B1 publication Critical patent/MA29785B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D291/00—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms
    • C07D291/08—Heterocyclic compounds containing rings having nitrogen, oxygen and sulfur atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Train Traffic Observation, Control, And Security (AREA)

Abstract

CETTE INVENTION CONCERNE DES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE I, (I) AINSI QUE DES SELS, DES HYDRATES, DES SOLVATES, DES COMPLEXES, ET DES PROMÉDICAMENTS ASSOCIÉS. CETTE INVENTION CONCERNE ÉGALEMENT DES MÉTHODES PERMETTANT DES SYNTHÉTISER LES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE I. EN OUTRE, CETTE INVENTION CONCERNE DES COMPOSITIONS PHARMACEUTIQUES COMPRENANT LES COMPOSÉS REPRÉSENTÉS PAR LA FORMULE I AFIN DE PRÉVENIR ET DE TRAITER DES TROUBLES ET DES MALADIES ASSOCIÉES AUX RÉCEPTEURS RYR QUI RÉGULENT LA FONCTION DU CANAL CALCIQUE DANS LES CELLULES.
MA30754A 2005-08-25 2008-03-17 Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr MA29785B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/212,413 US7704990B2 (en) 2005-08-25 2005-08-25 Agents for preventing and treating disorders involving modulation of the RyR receptors

Publications (1)

Publication Number Publication Date
MA29785B1 true MA29785B1 (fr) 2008-09-01

Family

ID=37772221

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30754A MA29785B1 (fr) 2005-08-25 2008-03-17 Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr

Country Status (35)

Country Link
US (1) US7704990B2 (fr)
EP (4) EP2177224B1 (fr)
JP (1) JP5342877B2 (fr)
KR (2) KR101456342B1 (fr)
CN (2) CN102558093B (fr)
AP (1) AP3091A (fr)
AR (1) AR057776A1 (fr)
AU (1) AU2006283534C1 (fr)
BR (1) BRPI0615097B1 (fr)
CA (1) CA2620183C (fr)
CR (1) CR9812A (fr)
CY (3) CY1113974T1 (fr)
DK (3) DK2311464T3 (fr)
EA (1) EA014941B1 (fr)
EC (1) ECSP088306A (fr)
ES (3) ES2405780T3 (fr)
GE (1) GEP20105134B (fr)
HK (3) HK1119705A1 (fr)
HN (1) HN2008000299A (fr)
HR (3) HRP20130353T1 (fr)
IL (1) IL189675A (fr)
MA (1) MA29785B1 (fr)
MY (1) MY144622A (fr)
NO (1) NO20081421L (fr)
NZ (1) NZ566822A (fr)
PL (3) PL2177224T3 (fr)
PT (3) PT2311464E (fr)
RS (3) RS52852B (fr)
SI (3) SI2311464T1 (fr)
SV (1) SV2008002828A (fr)
TN (1) TNSN08078A1 (fr)
TW (1) TWI486338B (fr)
UA (1) UA93388C2 (fr)
WO (1) WO2007024717A2 (fr)
ZA (1) ZA200802338B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US8022058B2 (en) * 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
JP2007525165A (ja) * 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
WO2008144483A2 (fr) * 2007-05-18 2008-11-27 Armgo Pharma, Inc. Agents de traitement de troubles comprenant la modulation de récepteurs de la ryanodine
CN101977902B (zh) 2008-03-03 2013-10-30 阿姆格药物公司 由γ-氨基烷基苯制备苯并硫氮杂*的方法
AU2008243144A1 (en) * 2008-11-06 2010-05-20 Quark Technologies Australia Pty Ltd Improvements in Radiopharmaceutical Purification
RU2011138955A (ru) 2009-02-25 2013-04-10 Нобору КАНЕКО Производные 1, 4-бензотиазепин-1-оксида и фармацевтическая композиция с использованием таких соединений
EP2418950A4 (fr) * 2009-04-15 2012-10-24 State Of Oregon By & Through The State Board Of Higher Education On Behalf Of Portland State Unv Composés et procédés de modulation de l'activité des canaux de libération de calcium
CN101812523B (zh) * 2010-04-09 2012-08-22 广州益善生物技术有限公司 Ryr1基因snp检测特异性引物、液相芯片和检测方法
WO2012019076A1 (fr) 2010-08-06 2012-02-09 The Trustees Of Columbia University In The City Of New York Compositions et méthodes de traitement prophylactique ou thérapeutique d'une lésion d'ischémie/reperfusion cardiaque
US9464322B2 (en) 2011-09-09 2016-10-11 University Of Kentucky Research Foundation Methods for diagnosing and treating alzheimer's disease (AD) using the molecules that stabilize intracellular calcium (Ca2+) release
EP2708535A1 (fr) * 2012-05-11 2014-03-19 Les Laboratoires Servier Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine
US9572528B1 (en) 2012-08-06 2017-02-21 Los Angeles Biomedical Research Insitute at Harbor-UCLA Medical Center Monitor for SIDS research and prevention
US10214574B2 (en) 2015-04-15 2019-02-26 Ohio State Innovation Foundation Engineered calmodulin for treatment of ryanopathies
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
EP3554258B1 (fr) 2016-12-15 2023-07-19 Société des Produits Nestlé S.A. Compositions et méthodes de modulation du phosphore ou des enzymes chez un animal de compagnie
EA202090231A1 (ru) * 2017-07-06 2020-06-08 Чилдренз Медикал Сентер Корпорейшн Композиции и способы лечения или профилактики катехоламинергической полиморфной желудочковой тахикардии
CN108588085B (zh) * 2018-05-30 2021-11-09 上海市第十人民医院 恶性心律失常的筛查试剂盒、动物模型的建立方法及应用
US11129871B1 (en) 2018-06-19 2021-09-28 Washington University Compositions and methods for treating and preventing endoplasmic reticulum (ER) stress-mediated kidney diseases
WO2021015221A1 (fr) 2019-07-22 2021-01-28 株式会社アエタスファルマ Procédé de production d'un dérivé de 1,4-benzothiazépine-1-oxyde optiquement actif
CA3177490A1 (fr) 2021-01-08 2022-07-14 Armgo Pharma, Inc. Formes cristallines d'un modulateur du recepteur de la ryanodine et leurs utilisations
WO2022246114A2 (fr) 2021-05-20 2022-11-24 Armgo Pharma, Inc. Compositions pharmaceutiques comprenant un modulateur du récepteur de la ryanodine et leurs utilisations

Family Cites Families (204)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1060786A (en) 1963-10-09 1967-03-08 Wander Ag Dr A Process for the preparation of lactams
US3519647A (en) 1966-10-12 1970-07-07 Squibb & Sons Inc 2,3,4,5-tetrahydro-1,5-benzothiazepines
DE3561317D1 (en) 1984-01-27 1988-02-11 Ajinomoto Kk Manufacture of heptanoic acid derivatives
US4567254A (en) 1984-09-19 1986-01-28 Kikkoman Corporation Method for preparing N6,8-disubstituted 3',5'-cyclic adenosine monophosphate and salt thereof
JPS6260A (ja) 1985-02-26 1987-01-06 Ajinomoto Co Inc シクロペンテニルヘプタン酸誘導体の製造方法
US4723012A (en) 1985-03-25 1988-02-02 Japan Tobacco Inc. Desmosine derivatives having a disulfide bond and preparation of artificial antigen using the same
US4841055A (en) 1985-03-25 1989-06-20 Japan Tobacco Inc. Desmosine derivatives and reagent for preparing artificial antigens
DE3677201D1 (de) 1986-03-27 1991-02-28 Topy Ind Oxidationskatalysator fuer kohlenmonoxyd.
US6956032B1 (en) 1986-04-18 2005-10-18 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
JPS63227599A (ja) 1987-03-14 1988-09-21 Kirin Brewery Co Ltd アンスラサイクリン化合物およびその用途
US5179125A (en) 1987-12-03 1993-01-12 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
US5210266A (en) 1987-12-03 1993-05-11 Dainippon Pharmaceutical Co., Ltd. N-substituted mercaptopropanamide derivatives
DE58901634D1 (de) 1988-11-05 1992-07-16 Bayer Ag Verfahren zur kernchlorierung von aromatischen kohlenwasserstoffen.
US5272164A (en) 1988-12-27 1993-12-21 Kirin Beer Kabushiki Kaisha Carboximidamide derivatives
US5223508A (en) 1988-12-27 1993-06-29 Kirin Beer Kabushiki Kaisha Pyridyl carboximidamide compounds useful in treating blood pressure
JPH0662567B2 (ja) 1988-12-27 1994-08-17 麒麟麦酒株式会社 ピリジンカルボキシイミダミド誘導体、その製造中間体、製造法および用途
US5142647A (en) 1989-04-18 1992-08-25 Japan Tobacco, Inc. Magnus measuring apparatus
CA1341094C (fr) * 1989-09-25 2000-09-05 Ronald G. Worton Diagnostic de l'hyperthermie maligne
ES2084706T3 (es) 1989-09-30 1996-05-16 Kirin Brewery Metodo de produccion de plantones.
US5075293A (en) 1989-10-10 1991-12-24 The Dow Chemical Company ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
US5153184A (en) 1989-10-10 1992-10-06 Dowelanco ((N-heterocyclyl)carbonyl)phosphoramidothioate ester insecticides
KR940000166B1 (ko) 1989-11-09 1994-01-08 니혼다바고 상교오 가부시기가이샤 신규 글루코사민 유도체 및 이것을 막 구성성분으로서 함유한 리포솜
US4963671A (en) 1989-11-20 1990-10-16 E. R. Squibb & Sons, Inc. Process for resolving chiral intermediates used in making calcium channel blockers
KR940003297B1 (ko) 1989-12-27 1994-04-20 니혼다바고 상교오 가부시기가이샤 1,3,2-디옥사티오렌옥시드 유도체
EP0480044A4 (en) 1990-03-30 1993-06-09 Japan Tobacco Inc. Novel 4h-3,1-benzoxazin-4-one derivative
JP2651043B2 (ja) 1990-07-10 1997-09-10 麒麟麦酒株式会社 ジフェニルメチルピペラジン誘導体
US5082847A (en) 1990-07-18 1992-01-21 Syntex (U.S.A.) Inc. Carbostyril compounds connected via an oxyalkyl group with a piperidine ring and having pharmaceutical utility
US5064810A (en) 1990-09-14 1991-11-12 Jeffrey Askanazi Use of branched chain amino acids to effect diaphragm contractility and fatigue
JP2703408B2 (ja) * 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
DE4102103A1 (de) 1991-01-25 1992-08-20 Bayer Ag Substituierte benzoxazepine und benzthiazepine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5332734A (en) 1991-04-10 1994-07-26 Japan Tobacco, Incorporated Oxazinone derivative
US5182272A (en) 1991-05-03 1993-01-26 G. D. Searle & Co. 8-substituted-dibenz[b,f][1,4]oxazepine-10(11)-carboxylic acid, substituted hydrazides, pharmaceutical compositions, and methods for treating pain
US5180720A (en) 1991-05-03 1993-01-19 G. D. Searle & Co. 2- and 3-alkoxy or hydroxy-8-substituted-dibenz[b,f]-[1,4]oxazepine-10(11H)-carboxylic acid, substituted hydrazides and methods for treating pain
CA2090677C (fr) 1991-07-04 1996-08-27 Yoshihiro Watanabe Methode de culture de cellules precurseurs de lymphocytes t
JP3239364B2 (ja) 1991-10-11 2001-12-17 ウェルファイド株式会社 骨粗鬆症治療薬およびジアゼピン化合物
AU3143593A (en) 1991-12-20 1993-07-28 G.D. Searle & Co. Substituted dibenzoxazepines or dibenzothiazepines and their use as prostaglandin E2 antagonists
MX9300433A (es) 1992-01-28 1994-07-29 Kirin Brewery Compuestos de piridincarboximidamina y composiciones farmaceuticas que los contienen.
GB9203347D0 (en) 1992-02-17 1992-04-01 Wellcome Found Hypolipidaemic compounds
JP2667351B2 (ja) 1992-03-24 1997-10-27 麒麟麦酒株式会社 食餌脂質消化吸収阻害剤および飲食品
US5387684A (en) 1992-03-25 1995-02-07 The Green Cross Corporation Isoindazole compound
JP3093419B2 (ja) 1992-03-30 2000-10-03 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
US5304644A (en) 1992-04-15 1994-04-19 G. D. Searle & Co. 1-,2-,3-,4-,5-,6-,7-,8- and/or 9 substituted dibenzoxazepine compounds, pharmaceutical compositions and methods for treating pain
US5478832A (en) 1992-05-08 1995-12-26 The Green Cross Corporation Quinoline compounds
HUT70049A (en) 1992-07-02 1995-09-28 Fujisawa Pharmaceutical Co Process for producing imidazole derivatives
CA2142883A1 (fr) 1992-08-21 1994-03-03 Saizo Shibata Compose de dioxacycloalkane ayant une activite inhibitrice de la renine
US5260286A (en) 1992-10-16 1993-11-09 Japan Tobacco, Inc. 2-piperidinecarboxylic acid derivatives useful as NMDA receptor antagonists
DE69317436T2 (de) 1992-11-09 1998-07-02 Knoll Ag 1,4-benzothiazepine verwendbar als neurologische mittel
US5354758A (en) 1992-12-16 1994-10-11 Japan Tobacco Inc. Benzomorphans useful as NMDA receptor antagonists
ZA94284B (en) * 1993-01-27 1994-08-17 Shionogi & Co Process for preparing benzothiazepine derivatives
ZA941003B (en) 1993-02-15 1995-08-14 Wellcome Found Hypolipidaemic compounds
IL108634A0 (en) 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
DE69416306T2 (de) 1993-04-15 1999-06-17 Kirin Beer K.K., Tokio/Tokyo Sphingoglycolipid und verwendung davon
US5354747A (en) 1993-06-16 1994-10-11 G. D. Searle & Co. 2-, 3-, 4-, 5-, 6-, 7-, 8-, 9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5461047A (en) 1993-06-16 1995-10-24 G. D. Searle & Co. 2-,3-,4-,5-,6-,7-,8-,9- and/or 10-substituted dibenzoxazepine and dibenzthiazepine compounds, pharmaceutical compositions and methods of use
US5824862A (en) 1993-08-19 1998-10-20 Japan Tobacco Inc. DNA encoding ATP-dependent fructose 6-phosphate 1-phosphotransferase originating from plant, recombinant vector containing the same and method for changing sugar content in plant cells under low temperature
FR2709753B1 (fr) 1993-09-09 1995-12-01 Hoechst Lab Nitrates organiques, leur procédé de préparation et leur application comme médicaments.
JPH08127594A (ja) 1993-11-10 1996-05-21 Mochida Pharmaceut Co Ltd Ｆａｓ抗原に結合する新規蛋白質およびそれをコードするＤＮＡ
EP0677519A4 (fr) 1993-11-10 1996-04-03 Japan Tobacco Inc Derive de chromanne et utilisation therapeutique de ce dernier.
US6897295B1 (en) 1993-11-10 2005-05-24 Mochida Pharmaceutical Co., Ltd. Antibodies and fragments thereof to Fas ligand and Fas ligand derived polypeptides
JP3914272B2 (ja) 1993-12-28 2007-05-16 中外製薬株式会社 アドゼベリンをコードする遺伝子
JP2706755B2 (ja) 1994-02-10 1998-01-28 日本たばこ産業株式会社 新規なベンジルアミノエトキシベンゼン誘導体
US5457182A (en) 1994-02-15 1995-10-10 Merck & Co., Inc. FK-506 cytosolic binding protein, FKBP12.6
US5449675A (en) 1994-06-09 1995-09-12 G. D. Searle & Co. Substituted dibenzoxazepine and dibenzthiazepine urea compounds, pharmaceutical compositions and methods of use
EP0764720B1 (fr) 1994-06-15 2005-12-14 Kirin Beer Kabushiki Kaisha Transferase et amylase, procede de production de ces enzymes, utilisation, et genes les codant
US20040175814A1 (en) 1994-06-15 2004-09-09 Kirin Beer Kubushiki Kaisha Novel transferase and amylase, process for producing the enzymes, use thereof, and gene coding for the same
ZA956647B (en) 1994-08-10 1997-02-10 Wellcome Found Hypolipidaemic compounds.
EP0741144B1 (fr) 1994-11-11 2002-07-24 Noboru Kaneko Anticorps monoclonal antiannexine-v, procede pour produire cet anticorps, et utilisation de cet anticorps
US5807850A (en) 1994-11-18 1998-09-15 Japan Tobacco, Inc. Therapeutic agent for osteoporosis and triazepine compound
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP3193301B2 (ja) 1995-09-14 2001-07-30 麒麟麦酒株式会社 生理活性タンパク質ｐ１６０
US6660837B1 (en) 1995-09-14 2003-12-09 Kirin Beer Kabushiki Kaisha Modified protein derived from protein kinase N
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
US5866341A (en) 1996-04-03 1999-02-02 Chugai Pharmaceutical Co., Ltd. Compositions and methods for screening drug libraries
US6362231B1 (en) 1996-07-08 2002-03-26 Nps Pharmaceuticals, Inc. Calcium receptor active compounds
JP3861187B2 (ja) * 1996-08-02 2006-12-20 住友精化株式会社 チアゼピン誘導体の製造方法
US6111072A (en) 1996-08-26 2000-08-29 Kirin Beer Kabushiki Kaisha Rho target protein human mDia and gene encoding same
JP4246264B2 (ja) 1996-12-12 2009-04-02 協和発酵キリン株式会社 新規β１→４Ｎ―アセチルグルコサミニルトランスフェラーゼ、それをコードする遺伝子
TW555562B (en) 1996-12-27 2003-10-01 Kirin Brewery Method for activation of human antigen-presenting cells, activated human antigen-presenting cells and use thereof
JP2894445B2 (ja) 1997-02-12 1999-05-24 日本たばこ産業株式会社 Ｃｅｔｐ活性阻害剤として有効な化合物
JP3521382B2 (ja) 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
US7112655B1 (en) 1997-02-27 2006-09-26 Japan Tobacco, Inc. JTT-1 protein and methods of inhibiting lymphocyte activation
JP3885177B2 (ja) 1997-03-26 2007-02-21 大塚製薬株式会社 ヒト遺伝子
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
DE19722317C1 (de) 1997-05-28 1998-10-08 Boehringer Ingelheim Int Das Protein des humanen Ryanodinrezeptors vom Typ 3 sowie dafür kodierende DNA-Moleküle
AUPO941497A0 (en) 1997-09-24 1997-10-16 Fujisawa Pharmaceutical Co., Ltd. Novel compounds
CA2274776C (fr) 1997-10-08 2008-11-25 Noboru Kaneko Procede d'analyse de l'annexine v dans l'urine et utilisation
GB9724813D0 (en) 1997-11-25 1998-01-21 Univ Nottingham Reducing muscle fatigue
JP2959765B2 (ja) 1997-12-12 1999-10-06 日本たばこ産業株式会社 ３−ピペリジル−４−オキソキナゾリン誘導体及びそれを含有してなる医薬組成物
AU1682699A (en) 1997-12-25 1999-07-19 Japan Tobacco Inc. Monoclonal antibody against connective tissue growth factor and medicinal uses thereof
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
US6051714A (en) 1998-03-12 2000-04-18 Reilly Industries, Inc. Processes for dechlorinating pyridines
BR9909666A (pt) 1998-03-26 2001-09-11 Japan Tobacco Inc Derivados de amida e antagonistas de nociceptina
SG74717A1 (en) 1998-04-10 2000-08-22 Japan Tobacco Inc Amidine compound
CA2319142A1 (fr) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Agents therapeutiques agissant sur les transporteurs membranaires
EP1122311A4 (fr) 1998-07-31 2002-04-17 Kirin Brewery Medicaments permettant de soigner la neuropathie contenant de la galectine-1 ou ses derives comme substance active
KR20010075107A (ko) 1998-09-17 2001-08-09 다께다 가즈히꼬 광화학 요법 치료제
ATE314852T1 (de) 1998-12-28 2006-02-15 Noboru Kaneko Verwendung von 1,4-benzothiazepinen zur herstellung eines medikaments zur behandlung der vorhof-fibrillation
DK1167537T3 (da) 1999-03-30 2008-11-10 Japan Tobacco Inc Fremgangsmåde til fremstilling af et monoklonalt antistof
AU774656B2 (en) 1999-05-19 2004-07-01 Noboru Kaneko Use of 1,4-benzothiazepine derivatives as drugs overcoming carcinostatic tolerance
GB9914745D0 (en) * 1999-06-24 1999-08-25 Knoll Ag Therapeutic agents
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
AU7097400A (en) 1999-09-01 2001-03-26 Otsuka Pharmaceutical Co., Ltd. Platelet membrane glycoprotein vi (gpvi) dna and protein sequences, and uses thereof
EP1222924B1 (fr) 1999-09-30 2006-12-27 Noboru Kaneko Agents anticancereux
TWI281915B (en) 1999-12-24 2007-06-01 Kirin Brewery Quinoline and quinazoline derivatives and drugs containing the same
US6649366B2 (en) 1999-12-29 2003-11-18 Smithkline Beecham Corporation Methods and compositions related to modulators of annexin and cartilage homeostasis
DE60109571D1 (de) 2000-01-14 2005-04-28 Migenix Corp Screening-assays unter verwendung von intramitochondrialem kalzium
BR0107733A (pt) 2000-01-20 2003-03-11 Eisai Co Ltd Composto, seu uso, composição farmacêutica, método para prevenir, tratar ou melhorar uma doença contra a qual um antogonista de cálcio é eficaz, método para suprimir uma morte cerebral neural ou proteger uma célula neural cerebral e método para prevenir, tratar ou melhorar doença neural ou dor
WO2001055118A1 (fr) * 2000-01-26 2001-08-02 Ono Pharmaceutical Co., Ltd. Derives heterocycliques condenses au benzene et medicaments contenant ceux-ci comme ingredients actifs
US6824973B2 (en) 2000-02-03 2004-11-30 Kirin Beer Kabushiki Kaisha Method of promoting stem cell proliferation or survival by contacting a cell with a stem cell factor-like polypeptide
WO2001060819A1 (fr) 2000-02-18 2001-08-23 Kirin Beer Kabushiki Kaisha Nouveaux composes d'isoxazole et de thiazole et leur utilisation en tant que medicaments
DE60116067T2 (de) 2000-03-24 2006-08-31 Pharmacia Corp., Chicago Amidino-verbindungen als hemmstoffe der stickstoffmonoxid-synthase
US6545170B2 (en) 2000-04-13 2003-04-08 Pharmacia Corporation 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
US6787668B2 (en) 2000-04-13 2004-09-07 Pharmacia Corporation 2-amino-4,5 heptenoic acid derivatives useful as nitric oxide synthase inhibitors
AR034120A1 (es) 2000-04-13 2004-02-04 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-4,5 heptenoico, composicion farmaceutica que lo comprende y el uso de dicho compuesto y dicha composicion en la fabricacion de un medicamento para inhibir o modular la sintesis de acido nitrico
AR032318A1 (es) 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa
US20040048780A1 (en) 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US20060293266A1 (en) 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7879840B2 (en) 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US7393652B2 (en) 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US7718644B2 (en) 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US6489125B1 (en) 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20030220312A1 (en) 2000-05-11 2003-11-27 G.D. Searle & Co. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
EP1280533A2 (fr) 2000-05-11 2003-02-05 Pharmacia Corporation Composition antagoniste de l'aldosterone destinee a etre liberee durant l'acrophase de l'aldosterone
JP3597140B2 (ja) 2000-05-18 2004-12-02 日本たばこ産業株式会社 副刺激伝達分子ａｉｌｉｍに対するヒトモノクローナル抗体及びその医薬用途
CN101498731A (zh) 2000-05-18 2009-08-05 日本烟草产业株式会社 抗协同刺激信号转导分子ailim的人单克隆抗体及其药物用途
WO2002002101A1 (fr) 2000-07-05 2002-01-10 Ajinomoto Co., Inc. Composes hypoglycemiques
EP1316548A4 (fr) 2000-07-05 2004-05-19 Ajinomoto Kk Derives d'acylsulfonamides
AU2001278045B2 (en) 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
EA005817B1 (ru) 2000-08-01 2005-06-30 Фармасиа Корпорейшн Производные гексагидро-7-1h-азепин-2-илгексановой (или гексеновой) кислоты в качестве ингибиторов индуцибельной синтазы оксида азота
AR031129A1 (es) 2000-09-15 2003-09-10 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-4-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
AR031608A1 (es) 2000-09-15 2003-09-24 Pharmacia Corp Derivados de los acidos 2-amino-2-alquil-3-hexenoico y -hexinoico utiles como inhibidores de oxido nitrico sintetasa
TWI290130B (en) 2000-09-15 2007-11-21 Pharmacia Corp 2-Amino-2alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
US6936426B2 (en) 2000-10-06 2005-08-30 Harbor-Ucla Research And Education Institute Detection of antibody mediated inflammatory auto-immune disorders
IL155977A0 (en) 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
US6673904B2 (en) 2000-12-23 2004-01-06 Kirin Beer Kabushiki Kaisha Stem cell growth factor-like polypeptides
US6962926B2 (en) 2001-01-31 2005-11-08 Telik, Inc. Antagonist of MCP-1 function, and compositions and methods of use thereof
US20050074762A1 (en) 2001-02-01 2005-04-07 Yusuke Nakamura Adiponectin-associated protein
JP4817514B2 (ja) 2001-03-09 2011-11-16 協和発酵キリン株式会社 新規動物細胞用ベクターおよびその使用
WO2002072145A1 (fr) 2001-03-14 2002-09-19 Ono Pharmaceutical Co., Ltd. Remedes antidepresseurs contenant un antagoniste ep1 en tant que principe actif
US20030054531A1 (en) 2001-03-19 2003-03-20 Decode Genetics Ehf, Human stroke gene
WO2002078625A2 (fr) 2001-03-28 2002-10-10 Pharmacia Corporation Combinaisons therapeutiques pour signes cardiovasculaires et inflammatoires
BRPI0209216B8 (pt) 2001-04-27 2021-05-25 Kyowa Hakko Kirin Co Ltd derivados de quinolina e de quinazolina, composições farmacêuticas compreendendo os mesmos e seus usos
JP4230681B2 (ja) 2001-07-06 2009-02-25 株式会社東芝 高耐圧半導体装置
US20030220310A1 (en) 2001-07-27 2003-11-27 Schuh Joseph R. Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
GB0121621D0 (en) * 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
CN1585638A (zh) 2001-09-14 2005-02-23 图拉里克公司 被连接的联芳基化合物
JP2003095977A (ja) * 2001-09-21 2003-04-03 Masafumi Yano 筋肉収縮・弛緩機能障害関連疾患の治療又は予防剤
JP4087338B2 (ja) 2001-11-15 2008-05-21 キリンファーマ株式会社 キメラ非ヒト動物
JP2003145746A (ja) 2001-11-16 2003-05-21 Seiko Epson Corp インクジェット記録方法及びインクジェット記録装置
EP1447096A1 (fr) 2001-11-19 2004-08-18 Ono Pharmaceutical Co., Ltd. Remedes pour la frequence urinaire
CA2469228A1 (fr) 2001-12-03 2003-06-12 Japan Tobacco Inc. Compose azole et utilisation medicinale de celui-ci
WO2003061699A1 (fr) 2001-12-27 2003-07-31 Japan Tobacco, Inc. Remedes pour affections allergiques
US20040171613A1 (en) 2001-12-27 2004-09-02 Japan Tobacco Inc. Therapeutic agent for non-immediate type allergic diseases
MXPA04006255A (es) 2002-01-17 2004-09-27 Pharmacia Corp Compuestos novedosos de alquil/aril hidroxi o ceto tiepina como inhibidores del transporte del acido biliar codependiente del sodio apical y la captacion de taurocolato.
CN100543022C (zh) 2002-02-01 2009-09-23 大日本住友制药株式会社 2-呋喃甲酸酰肼化合物及含该化合物的药物组合物
US20060233902A1 (en) 2002-02-14 2006-10-19 Kirin Beer Kabushiki Kaisha Compositions and foods for improving lipid metabolism
US7439332B2 (en) 2002-04-26 2008-10-21 Kirin Pharma Kabushiki Kaisha Polypeptide having an activity to support proliferation or survival of hematopoietic stem or progenitor cells
JPWO2003090570A1 (ja) 2002-04-26 2005-08-25 日本たばこ産業株式会社 棒状物品の成形装置
JP4113042B2 (ja) 2002-05-24 2008-07-02 シチズンホールディングス株式会社 表示装置およびカラー表示方法
DE10237723A1 (de) 2002-08-17 2004-07-08 Aventis Pharma Deutschland Gmbh Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
JP2004103256A (ja) 2002-09-04 2004-04-02 Nippon Chemicon Corp 非常灯
CA2502583A1 (fr) 2002-09-12 2004-03-25 Kirin Beer Kabushiki Kaisha Derives d'isoquinoline d'inhibition des kinases et medicaments contenant ceux-ci
BR0314640A (pt) 2002-09-20 2005-08-02 Kirin Brewery Inibidor de vìrus de hepatite c compreendendo, como um ingrediente ativo, alfa-glicosilceramida
US20060185025A1 (en) 2002-10-04 2006-08-17 Kirin Beer Kabushiki Kaisha Human artificial chromosome (hac) vector
US7544678B2 (en) 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
WO2004042389A2 (fr) 2002-11-08 2004-05-21 Bayer Healthcare Ag Moyens diagnostiques et therapeutiques destines a des maladies associees a la phosphodiesterase 4d (pde4d) humaine
WO2004047755A2 (fr) 2002-11-22 2004-06-10 Japan Tobacco Inc. Heterocycles contenant de l'azote bicyclique fusionne
EP1439221B1 (fr) 2002-12-17 2007-01-24 F. Hoffmann-La Roche Ag Construction dérivée du noyau de PDE
AR045414A1 (es) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
JP2007525165A (ja) 2003-03-07 2007-09-06 トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク タイプ１ライアノジン受容体に基づく方法
TWI220798B (en) 2003-03-07 2004-09-01 Hitachi Cable Light-emitting diode array
PT1603553E (pt) 2003-03-17 2012-02-03 Japan Tobacco Inc Composições farmacêuticas de inibidores de cetp
BRPI0408442A (pt) 2003-03-17 2006-04-04 Japan Tobacco Inc método para aumento da biodisponibilidade oral de s-[2-([[1-(2-etilbutil)ciclohexil]carbonil]amino)fenil]2- metilpropanotioato
CL2004000544A1 (es) 2003-03-18 2005-01-28 Pharmacia Corp Sa Organizada B Uso de una combinacion farmaceutica, de un antagonista del receptor de aldosterona y un inhibidor de endopeptidasa neutral, util para el tratamiento y prevencion de una condicion patologica relacionada con hipertension, disfuncion renal, insulinopati
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
WO2004085382A1 (fr) 2003-03-27 2004-10-07 Kirin Beer Kabushiki Kaisha Compose inhibiteur in vivo de transport de phosphore et medicament en contenant
BRPI0409136A (pt) 2003-04-09 2006-04-25 Japan Tobacco Inc composto heteroaromático pentacìclico e uso medicinal do mesmo
US20050009733A1 (en) 2003-04-22 2005-01-13 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a potassium ion channel modulator for the treatment of central nervous system damage
WO2004093813A2 (fr) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions renfermant un inhibiteur selectif a l'egard de la cyclooxygenase 2 et un agent de modulation du calcium pour le traitement de la douleur, de l'inflammation ou de troubles dus a l'inflammation
WO2004093816A2 (fr) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions renfermant un inhibiteur selectif de cyclo-oxygenase-2 et un agent modulateur de calcium pour le traitement de dommages au systeme nerveux central
WO2004093895A1 (fr) 2003-04-22 2004-11-04 Pharmacia Corporation Compositions d'inhibiteur selectif de la cyclooxygenase-2 et de modulateur de canal d'ion potassium pour le traitement de la douleur, des inflammations et des troubles induits par des inflammations
TWI494102B (zh) 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2005016249A2 (fr) 2003-07-11 2005-02-24 Pharmacia Corporation Compositions constituees d'un inhibiteur chromene ou acide phenylacetique selectif de la cyclooxygenase-2 et d'un inhibiteur de ace pour traiter les lesions du systeme nerveux central
WO2005013907A2 (fr) 2003-08-07 2005-02-17 Japan Tobacco Inc. Derives de pyrrolo[1,2-b]pyridazine
CA2536173A1 (fr) 2003-08-20 2005-03-03 Nitromed, Inc. Composes cardiovasculaires nitroses et nitrosyles, compositions et procedes d'utilisation
CA2536967A1 (fr) 2003-08-28 2005-03-17 Nitromed, Inc. Composes cardiovasculaires nitroses et nitrosyles, compositions et procedes d'utilisation correspondants
US20050187221A1 (en) 2003-09-08 2005-08-25 Japan Tobacco Inc. Method of treating ischemia reperfusion injury
JP2007515490A (ja) 2003-12-22 2007-06-14 アムジェン インコーポレーティッド アリールスルホンアミド化合物およびそれに関連する使用法
US7165879B2 (en) 2004-03-25 2007-01-23 Red Devil Equipment Company Clamp lock apparatus and method for a paint mixer
JP2007533328A (ja) 2004-04-22 2007-11-22 キリンホールディングス株式会社 トランスジェニック動物及びその用途
EP1743895A4 (fr) 2004-04-28 2010-06-16 Aetas Pharma Co Ltd Accélérateur du relachement des muscles et agent thérapeutique pour des maladies des tissus musculaires telles qu'une insuffisance du relâchement des muscles
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP3968358B2 (ja) 2004-06-30 2007-08-29 日本電信電話株式会社 薄型フラットツイストぺアすきまケーブル及びすきまナビゲータユニット
CN1984906A (zh) 2004-07-15 2007-06-20 日本烟草产业株式会社 稠合苯甲酰胺化合物和香草素受体1(vr1)活性抑制剂
JP2006094849A (ja) 2004-08-30 2006-04-13 Kirin Brewery Co Ltd 相同組換え効率が向上した分化多能性細胞及びその利用
AR051780A1 (es) 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
JP2008531579A (ja) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド 酸化窒素増強利尿化合物、組成物および使用方法
CA2599544A1 (fr) 2005-02-28 2006-09-08 Japan Tobacco Inc. Nouveau compose aminopyridine ayant une activite d'inhibition de la syk
WO2006098394A1 (fr) 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
US7704990B2 (en) 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors

Also Published As

Publication number Publication date
SI2311464T1 (sl) 2013-06-28
AU2006283534B2 (en) 2010-11-04
PL1928850T3 (pl) 2013-11-29
ES2421159T3 (es) 2013-08-29
CY1113974T1 (el) 2016-07-27
ECSP088306A (es) 2008-07-30
EA200800665A1 (ru) 2008-08-29
UA93388C2 (uk) 2011-02-10
DK1928850T3 (da) 2013-09-23
EP2764867A1 (fr) 2014-08-13
MY144622A (en) 2011-10-14
SI2177224T1 (sl) 2013-06-28
EP2177224A3 (fr) 2010-06-30
DK2177224T3 (da) 2013-05-13
PT2177224E (pt) 2013-05-15
SV2008002828A (es) 2010-07-20
CN102558093A (zh) 2012-07-11
HK1137150A1 (en) 2010-07-23
US20070049572A1 (en) 2007-03-01
CY1114091T1 (el) 2016-07-27
WO2007024717A2 (fr) 2007-03-01
JP2009506034A (ja) 2009-02-12
HN2008000299A (es) 2011-07-11
RS52852B (en) 2013-12-31
CN101500576B (zh) 2013-08-14
BRPI0615097A2 (pt) 2009-07-14
EP2311464B1 (fr) 2013-02-13
DK2311464T3 (da) 2013-05-13
CA2620183C (fr) 2014-04-15
EP1928850B1 (fr) 2013-06-19
WO2007024717A3 (fr) 2009-01-08
AR057776A1 (es) 2007-12-19
RS52781B (en) 2013-10-31
AU2006283534C1 (en) 2012-08-02
TW200800930A (en) 2008-01-01
KR20120025626A (ko) 2012-03-15
AP3091A (en) 2015-01-31
ES2405780T3 (es) 2013-06-03
HRP20130360T1 (hr) 2013-06-30
NZ566822A (en) 2011-04-29
CR9812A (es) 2009-09-14
JP5342877B2 (ja) 2013-11-13
EA014941B1 (ru) 2011-04-29
EP1928850A4 (fr) 2009-06-17
CN101500576A (zh) 2009-08-05
EP2177224A2 (fr) 2010-04-21
NO20081421L (no) 2008-05-23
RS52780B (en) 2013-10-31
TWI486338B (zh) 2015-06-01
IL189675A (en) 2013-12-31
ZA200802338B (en) 2009-01-28
CN102558093B (zh) 2014-10-15
IL189675A0 (en) 2008-06-05
GEP20105134B (en) 2010-12-27
PL2311464T3 (pl) 2013-07-31
EP1928850A2 (fr) 2008-06-11
HRP20130669T1 (hr) 2013-08-31
HK1153664A1 (en) 2012-04-05
AU2006283534A1 (en) 2007-03-01
EP2311464A1 (fr) 2011-04-20
PT1928850E (pt) 2013-08-23
ES2405765T3 (es) 2013-06-03
PL2177224T3 (pl) 2013-07-31
CY1113975T1 (el) 2016-07-27
BRPI0615097B1 (pt) 2021-06-01
KR101456342B1 (ko) 2014-11-03
CA2620183A1 (fr) 2007-03-01
HK1119705A1 (en) 2009-03-13
SI1928850T1 (sl) 2013-09-30
TNSN08078A1 (en) 2009-07-14
PT2311464E (pt) 2013-05-15
HRP20130353T1 (hr) 2013-06-30
US7704990B2 (en) 2010-04-27
KR20080037741A (ko) 2008-04-30
EP2177224B1 (fr) 2013-02-27

Similar Documents

Publication Publication Date Title
MA29785B1 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
MY153263A (en) Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels
MY145070A (en) Imidazolothiazole compounds for the treatment of disease
MX2010002674A (es) Moduladores de gamma secretasa.
TNSN07305A1 (fr) Agonistes de pyy et leurs utilisations
TW200626068A (en) Active compounds for seed treatment
MY162157A (en) Substituted indole mcl-1 inhibitors
MA32150B1 (fr) Inhibiteurs heterocycliques de la stearoyl-coa desaturase
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2007016469A (es) Metodos de tratamiento utilizando ansamicinas de hidroquinona.
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
MA30557B1 (fr) Composés de pyrrolopyrimidine et leurs utilisations.
NO20083220L (no) Heterocykliske derivater som modulatorer for ionekanaler
NO20082880L (no) Inhibitorer av C-MET samt anvendelse derav
MX2010002712A (es) Compuestos que modulan calcio intracelular.
MA31001B1 (fr) Quinazolines destines a l'inhibition de pdk
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
MX2007009356A (es) Compuestos y composiciones como moduladores de ppar.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
NO20064325L (no) Heteroarylaminopyrazolderivativer nyttige for behandling av diabetes
MA29377B1 (fr) Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif
MX2010005028A (es) Moduladores de gamma secretasa.
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MX2008013196A (es) 5-amido-2-carboxiamida-indoles.
UA99901C2 (en) Indole compounds